/
RDY
$14.49-$0.37 (-2.49%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$12.8B
833M shares
52-week range
$12.19 – $15.67
66% from low
Exchange
NYSE
ADRC
Borrow rate
0.86%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-0.55
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $153.85B | $174.60B | $2.56B | $214.39B | $245.88B | $279.16B | $325.54B | $353.47B |
| Cost of revenue | $70.42B | $80.59B | $1.26B | $100.55B | $106.54B | $115.56B | $135.11B | $166.95B |
| Gross profit | $83.43B | $94.01B | $1.30B | $113.84B | $139.34B | $163.61B | $190.43B | $186.52B |
| Gross margin | 54.2% | 53.8% | 50.8% | 53.1% | 56.7% | 58.6% | 58.5% | 52.8% |
| R&D | $15.61B | $15.41B | $208.4M | $17.48B | $19.38B | $22.87B | $27.38B | $25.31B |
| Operating income | $20.89B | $15.99B | $431.4M | $29.48B | $57.14B | $67.73B | $71.84B | $48.87B |
| EBITDA | $35.52B | $41.78B | $534.8M | $45.08B | $74.43B | $88.42B | $96.67B | $83.29B |
| Net income | $18.80B | $19.50B | $232.2M | $23.57B | $45.07B | $55.68B | $56.54B | $45.09B |
| Net margin | 12.2% | 11.2% | 9.1% | 11.0% | 18.3% | 19.9% | 17.4% | 12.8% |
| EPS (diluted) | 113.09 | 117.40 | 20.73 | 28.34 | 54.17 | 66.80 | 67.77 | 53.92 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $355.0B | $50.72 | $45.93–$56.46 | 2 |
| 2028 | $392.5B | $62.58 | $55.84–$71.24 | 2 |
| 2029 | $430.4B | $75.57 | $68.54–$86.77 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$16.33
Price
$14.49
Implied upside
+13%
Peer comparison
Dr. Reddy's Laboratories Limited American Depositary Shares
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
www.drreddys.com- Employees
- 27,527
- IPO / List date
- Apr 11, 2001
Held by traders on TradeandTell
No one on the platform currently holds RDY.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 7,859,728 | $108.9M |
Insider activity (SEC Form 4)
Dividend history
TTM yield · 7.82% ($1.13/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-07-24 | $0.0834 | |
| 2025-07-25 | $0.0915 | 2025-08-06 |
| 2024-07-30 | $0.4762 | 2024-08-12 |
| 2023-07-28 | $0.4826 | 2023-08-11 |
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-11-05 | 5-for-1 |
| 2006-09-07 | 2-for-1 |
Recent trades on TradeandTell
No one on the platform has traded RDY yet.
